Related Experiment Video
Updated: Jul 11, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Congenital hypothyroidism control programs. A cost-benefit analysis
Insights
Screening neonates for congenital hypothyroidism (CH) is cost-effective. Early detection and treatment of CH prevent mental retardation, offering significant economic benefits that outweigh program costs.
Area of Science:
- Public Health
- Pediatrics
- Endocrinology
Background:
- Congenital hypothyroidism (CH) is a preventable cause of mental retardation.
- Early screening and intervention are crucial for managing CH.
- Public health agencies are evaluating comprehensive CH screening programs.
Purpose of the Study:
- To assess the cost-effectiveness of newborn screening for congenital hypothyroidism (CH).
- To determine the economic benefits of early CH detection and treatment.
Main Methods:
- Analysis of costs associated with CH screening, including specimen collection, laboratory analysis, and follow-up.
- Calculation of present value for treatment costs and economic benefits (averted institutionalization, special education, increased productivity).
Main Results:
- The estimated cost to detect and treat a single case of CH is $11,800.
- Economic benefits, including averted costs and increased productivity, are estimated at $105,000 per case.
- The cost-benefit ratio for CH screening and treatment is approximately 1:8.9.
Conclusions:
- Newborn screening for congenital hypothyroidism is highly cost-effective.
- Implementing CH screening programs yields substantial economic benefits, significantly outweighing the costs.
- Early detection and treatment of CH are vital for preventing mental retardation and improving long-term outcomes.
Abstract:
Comprehensive screening programs to control congenital hypothyroidism (CH), a preventable form of mental retardation, are being considered by some public health agencies. The proposed programs would test neonates' blood for thyroxine and, if warranted, provide follow-up testing and therapy. The estimated cost of detecting a single case of CH is $9,300, which includes specimen collection, laboratory analysis, and retesting of border-line cases. The present value of the treatment costs of CH adds $2,500 per case, a total cost of $11,800 per case detected and child treated. The economic benefits (averted costs of institutionalization and special education and increased productivity of the affected person) are estimated to have a present value of $105,000 per case, yielding a cost-benefit ratio of 1:8.9.
Related Concept Videos
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Aneurysm III: Interprofessional Care

